TrialNeuro-oncology2023

A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokinetics.

Priya U Kumthekar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.